NEW YORK – November 06, 2023 – Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has closed on a $20 million term loan from HSBC Innovation Banking, a division of HSBC Bank USA, N.A. The term loan was partially drawn at closing, with the proceeds used to retire Click’s previous term loan. The undrawn balance remains fully available to help advance Click’s prescription digital therapeutic pipeline.

“The last few years have been a period of tremendous growth for Click, and we could not be more excited to partner with HSBC Innovation Banking, a leader in the innovation economy,” said Randall Stanicky, Chief Financial Officer of Click Therapeutics. “We are pleased with the financial terms, which we believe reflect Click’s leadership in the industry and the progress we have made towards profitability. This capital will help us continue to fund important investments in our platform and pipeline.”

Click Therapeutics has announced four major co-development and commercialization collaborations to date for the treatment of major depressive disorder (MDD), schizophrenia, and substance use disorders. Click is also progressing its lead internal program for the preventive treatment of migraine with pivotal data expected in 2024.

“This is an exciting opportunity for HSBC Innovation Banking to partner with a truly innovative company in the digital therapeutic space” said Clark Hayes, Head of Business Development, Healthcare and Life Sciences for HSBC Innovation Banking. “As Randall and his team look to grow their business, HSBC’s innovation network, combined with our size, strength, and international footprint, creates endless opportunity for Click at every phase of its growth.”

Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. We are expanding the possibilities of medicine with Digital Therapeutics™ that combine clinical science with the power of software to create a new way to treat disease.  

Operating at the intersection of biology and technology, we use a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes, consistently. Digital therapeutics on Click’s platform are regulated, clinically validated prescription mobile applications that can address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. 

Click Therapeutics, in collaboration with Otsuka, developed the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms, Rejoyn™. In October 2024, in response to FDA guidance on prescription drug use-related software (PDURS), we launched Click SE™ to extend our digital therapeutics platform and expertise to the development of software-enhanced drug™ therapies that combine software with pharmacotherapy to offer added clinically meaningful benefit to patients.

Our commitment to advancing digital medicine means we continually improve our platform technologies, ensuring we stay at the forefront of cognitive, behavioral, and neuromodulatory therapeutic innovation, to achieve the best possible outcomes for patients. Our diverse team of innovators—spanning clinicians, researchers, technologists, designers and more—works together to create cutting-edge digital therapeutics, united in the mission to transform patient care. For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn.

HSBC Bank USA, National Association (HSBC Bank USA, N.A.) serves customers through Wealth and Personal Banking, Commercial Banking, Private Banking, Global Banking, and Markets and Securities Services. It operates Wealth Centers in: California; Washington, D.C.; Florida; New Jersey; New York; Virginia; and Washington. HSBC Bank USA, N.A. is the principal subsidiary of HSBC USA Inc., a wholly-owned subsidiary of HSBC North America Holdings Inc. In the United States, deposit products are offered by HSBC Bank USA, N.A., Member FDIC.

For more information, please visit: https://www.us.hsbc.com/